RYTMRhythm Pharmaceuticals, Inc. Common Stock

CSNasdaq (XNAS)·USD

Identity

Security key: 21242
Ticker: RYTM
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2017-10-05
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: RYTM

Detail

Enriched 2026-08-14 20:47

Market cap: $8,097,004,843.2
Shares outstanding (class): 68,532,607
Shares outstanding (weighted): 68,852,082
SIC: 2834 PHARMACEUTICAL PREPARATIONS
Employees: 414
Location: BOSTON, MA
Homepage: https://www.rhythmtx.com
Description: Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Market cap and share counts drift.

Funds holding this security

181 funds · 185 positions · $1.33B reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$189.30M	0.01%	2,176,619 NS	FIGI
VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS	VB	$136.93M	0.08%	1,574,414 NS	FIGI
iShares Russell 2000 ETF iShares Trust	IWM	$112.40M	0.16%	1,292,397 NS	FIGI
SMALLCAP World Fund Inc SMALLCAP World Fund Inc	—	$93.89M	0.12%	1,079,599 NS	FIGI
State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST	XBI	$81.85M	1.10%	941,162 NS	FIGI
VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS	VBK	$76.55M	0.20%	880,146 NS	FIGI
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$59.01M	0.07%	678,467 NS	FIGI
JPMorgan Mid Cap Growth Fund JPMorgan Trust II	—	$51.94M	0.46%	597,190 NS	FIGI
T. Rowe Price New Horizons Fund, Inc. T. ROWE PRICE NEW HORIZONS FUND, INC.	—	$43.19M	0.34%	496,569 NS	FIGI
iShares Biotechnology ETF iShares Trust	IBB	$41.27M	0.51%	474,539 NS	FIGI
iShares Russell 2000 Growth ETF iShares Trust	IWO	$37.51M	0.31%	431,261 NS	FIGI
T. Rowe Price Integrated U.S. Small-Cap Growth … T. ROWE PRICE INTEGRATED EQUITY FUNDS, INC.	—	$31.14M	0.38%	358,073 NS	FIGI
Putnam Small Cap Growth Fund Putnam Funds Trust	—	$24.08M	0.89%	276,855 NS	FIGI
Loomis Sayles Small Cap Growth Fund LOOMIS SAYLES FUNDS II	—	$22.62M	1.17%	260,101 NS	FIGI
JPMorgan Small Cap Growth Fund JPMorgan Trust II	—	$22.21M	1.02%	255,372 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERRYTM
FIGI_COMPOSITEBBG007DLZ601
FIGI_SHARE_CLASSBBG007DLZ629
CIK0001649904
ISINUS76243J1051
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Pharmaceuticals
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Rhythm Pharmaceuticals is a biopharmaceutical company focused on rare genetic obesity, classified under pharmaceutical preparations.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.